As the battle for the generic market for off-patent drugs in the US intensifies, Indian companies remain at the top in filing drug master files (DMFs) with the US Food and Drug Administration......
Schwarz Pharma AG of Germany has discontinued the development of Ranbaxy Laboratories' RBx 2258 molecule, meant to treat benign prostate hyperplasia. This has put a question mark on the $42-million......